Rivoceranib
- Generic Name
- Rivoceranib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C24H23N5O
- CAS Number
- 811803-05-1
- Unique Ingredient Identifier
- 5S371K6132
- Background
Rivoceranib is under investigation in clinical trial NCT02726854 (Apatinib as Second-line Treatment of Advanced Pancreatic Cancer).
- Indication
本品单药适用于既往至少接受过2种系统化疗后进展或复发的晚期胃腺癌或胃-食管结合部腺癌患者。患者接受治疗时应一般状况良好。
- Associated Conditions
- -
- Associated Therapies
- -
Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer
- First Posted Date
- 2018-12-14
- Last Posted Date
- 2018-12-14
- Target Recruit Count
- 80
- Registration Number
- NCT03775928
- Locations
- 🇨🇳
Cancer hospital, ChineseAMS, Beijing, Beijing, China
A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC
- Conditions
- Interventions
- First Posted Date
- 2018-12-05
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 543
- Registration Number
- NCT03764293
- Locations
- 🇺🇸
Renovatio Clinical, The Woodlands, Texas, United States
🇨🇳The 940th Hospital of the joint logistic support force of People's Liberation Army, Lanzhou, Gansu, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Apatinib Combined With Chemotherapy for NSCLC Patients Without T790M Mutation
- First Posted Date
- 2018-11-29
- Last Posted Date
- 2020-07-23
- Lead Sponsor
- The First Hospital of Jilin University
- Target Recruit Count
- 30
- Registration Number
- NCT03758677
- Locations
- 🇨🇳
The First Hospital of Jilin University, Changchun, Jilin, China
Pulmonary Resectable Metastases of Osteosarcoma With Anti-angiogenics and CHemotherapy
- Conditions
- Interventions
- First Posted Date
- 2018-11-15
- Last Posted Date
- 2023-11-01
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 43
- Registration Number
- NCT03742193
- Locations
- 🇨🇳
Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
TMZ Plus Apatinib in Newly Diagnosed High-grade Glioma：RCT
- First Posted Date
- 2018-11-14
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- The Second Hospital of Hebei Medical University
- Target Recruit Count
- 211
- Registration Number
- NCT03741244
- Locations
- 🇨🇳
the Second Hospital of Hebei Medical University, Shijiazhuang, China
Apatinib Combined With Paclitaxel and Carbopatin Intensive Regimen in Neoadjuvant Therapy for Locally Advanced Triple-negative Breast Cancer
- First Posted Date
- 2018-11-08
- Last Posted Date
- 2018-11-08
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 29
- Registration Number
- NCT03735082
- Locations
- 🇨🇳
Cancer Hospital, ChineseAMS, Beijing, Beijing, China
Apatinib for Advanced Lung Squmamous Carcinoma
- First Posted Date
- 2018-10-31
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- Xuzhou Central Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT03725423
SHR-1210 Plus Apatinib in Patients With Hepatocellular Carcinoma After Surgery
- First Posted Date
- 2018-10-29
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 45
- Registration Number
- NCT03722875
- Locations
- 🇨🇳
Zhongshan Hospital, Shanghai, Shanghai, China
A Study of Intraperitoneal and Intravenous Paclitaxel Plus Apatinib and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells
- Conditions
- Interventions
- First Posted Date
- 2018-10-24
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- Hebei Medical University
- Target Recruit Count
- 36
- Registration Number
- NCT03718624
Efficacy and Safety of Apatinib as Third-line Therapy for Primary Pulmonary Lymphoepithelioid Carcinoma
- First Posted Date
- 2018-10-17
- Last Posted Date
- 2018-10-24
- Lead Sponsor
- Guangzhou Institute of Respiratory Disease
- Target Recruit Count
- 33
- Registration Number
- NCT03709953
- Locations
- 🇨🇳
Zhou Chengzhi, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.